|2.||Neoplasm Metastasis (Metastasis)
|3.||Colorectal Neoplasms (Colorectal Cancer)
|4.||Breast Neoplasms (Breast Cancer)
|5.||Colonic Neoplasms (Colon Cancer)
|1.||Fuchs, Charles S: 168 articles (04/2016 - 03/2002)|
|2.||Ogino, Shuji: 101 articles (04/2016 - 09/2005)|
|3.||Lenz, Heinz-Josef: 84 articles (11/2015 - 01/2002)|
|4.||Giovannucci, Edward: 80 articles (04/2016 - 08/2002)|
|5.||Mori, Masaki: 76 articles (10/2015 - 01/2002)|
|6.||Goldberg, Richard M: 76 articles (08/2015 - 02/2002)|
|7.||Van Cutsem, Eric: 75 articles (12/2015 - 04/2002)|
|8.||Potter, John D: 72 articles (12/2015 - 01/2002)|
|9.||Chan, Andrew T: 69 articles (04/2016 - 08/2005)|
|10.||Meyerhardt, Jeffrey A: 68 articles (12/2015 - 04/2004)|
|1.||Fluorouracil (Carac)FDA LinkGeneric
01/01/1986 - "5-Fluorouracil as a single agent has shown the best results to date, and is the treatment of first choice but no treatment has been shown to prolong survival unequivocally in colorectal cancer. "
08/01/2000 - "Synergistic with 5-FU in colorectal cancer (CRC), the combination has proven efficacy in 5-FU-resistant advanced disease and in previously untreated CRC, as demonstrated in controlled phase III trials, while evaluation in the adjuvant setting is ongoing. "
04/01/1996 - "Although no optimal combination dose schedule of LV is well known, randomized studies have shown improved activity of 5-FU modulation by LV over 5-FU alone for advanced colorectal cancer doubled the response rate by monotherapy (20-25%) vs 10-15%). "
06/01/1995 - "From the present study, l-LV and 5-FU combination therapy seems to be a very promising and useful treatment for patients with advanced colorectal carcinoma."
10/01/2009 - "The MTHFR 677C>T and 1298A>C polymorphisms probably do not predict efficacy of adjuvant 5-FU treatment in colorectal cancer after complete resection; however, the 677C>T polymorphism may be associated with lower toxicity in 5-FU treatment. "
|2.||irinotecan (Camptosar)FDA LinkGeneric
11/21/2015 - "After irinotecan was introduced for the treatment of metastatic colorectal cancer (CRC) at the end of the last century, survival has improved dramatically. "
11/01/2001 - "Weekly CPT-11/5-FU/FA is highly effective in the treatment of patients with metastatic colorectal cancer limited to the liver, even after failure of previous 5-FU/FA. "
01/01/2010 - "To (i) identify the optimal regimen for IFL therapy in terms of irinotecan dosage, and (ii) determine the maximum tolerated dose and efficacy of the modified-IFL regimen in patients with histologically confirmed advanced colorectal cancer. "
08/01/2000 - "Thus, considering other encouraging data from the literature, the CPT-11 + FU-LV combination therapy can be regarded as a new, very effective treatment option for first-line treatment of advanced colorectal cancer patients."
01/01/2008 - "This study aimed to determine the safety and efficacy of high-dose (HD) irinotecan combined with LV5FU2 or simplified LV5FU (LV5FUs) in first-line treatment of metastatic colorectal cancer. "
|3.||oxaliplatin (Eloxatin)FDA LinkGeneric
08/23/2012 - "In contrast, oxaliplatin, containing the isomeric 1(R),2(R)-DACH carrier ligand, enjoys worldwide clinic application as a most important therapeutic agent in the treatment of colorectal cancer. "
10/01/2002 - "To date, oxaliplatin has proven to be a safe and effective therapy for colorectal cancer and side effects have been easy to manage with appropriate awareness from patients and care providers."
01/01/2004 - "Oxaliplatin combined with the bolus Nordic schedule of FU+FA (Nordic FLOX) is a well-tolerated, effective, and feasible bolus schedule as first-line treatment of metastatic colorectal cancer that yields comparable results compared with more complex schedules."
10/01/2003 - "Although no definitive data show one drug to be better than the other, several arguments favored the oxaliplatin/5-FU combination as a first-line treatment of metastatic colorectal cancer. "
01/01/2003 - "Oxaliplatin combined with the bolus Nordic schedule of 5-FU/ FA (Nordic FLOX) appears to be well tolerated, effective and feasible as first-line treatment of metastatic colorectal cancer yielding results comparable with those obtained by more complex schedules."
|4.||Leucovorin (Folinic Acid)FDA Link
10/01/1991 - "Recent clinical trials have demonstrated that both the response rate and the survival time of patients with advanced colorectal cancer can be significantly improved by the addition of leucovorin (CF) to FUra. "
03/01/1990 - "These results suggest that the efficacy of FUra in patients with advanced, measurable, metastatic colorectal cancer can be enhanced significantly by administration of a continuous high-dose infusion of leucovorin calcium."
10/01/2000 - "However, because knowledge and experience with UFT plus leucovorin are relatively limited in Japan, we conducted a phase II study to evaluate the safety and efficacy of this combination in Japanese patients with metastatic colorectal cancer. "
01/01/2001 - "The application for FDA approval of UFT with leucovorin as a first-line treatment regimen for advanced colorectal cancer is pending. "
06/01/2000 - "Efficacy of UFT plus oral leucovorin in advanced colorectal cancer: a multicenter study."
11/01/2011 - "We report an extremely aged patient case of metastatic colorectal cancer that was treated successfully with modified FOLFOX6 (mFOLFOX6) plus bevacizumab therapy. "
06/01/2011 - "Since the most frequent genetic alteration of colorectal cancer is KRAS mutation we have analyzed its effect on the efficacy of Avastin treatment. "
08/01/2005 - "Reviewing key clinical evidence that can help inform decision-making, this article addresses important questions in colorectal cancer management, including: Should bevacizumab (Avastin) be a component of most patients' first-line treatment? "
01/01/2012 - "Bevacizumab has an important role in first-line treatment of metastatic colorectal cancer. "
08/01/2013 - "Clinical studies have shown that bevacizumab beyond progression to first line therapy is beneficial for overall survival in advanced stage colorectal cancer. "
|6.||cetuximab (Erbitux)FDA Link
01/01/2013 - "In the CRYSTAL study adding cetuximab to first-line FOLFIRI significantly improved outcome in patients with KRAS wild-type metastatic colorectal cancer. "
04/01/2010 - "In subgroup analysis, in colorectal cancer, there was a significant improvement of PFS (0.72, 0.66-0.78), OS (0.90, 0.81-1.00), and ORR in the cetuximab group (1.36, 1.15-1.60). "
06/01/2015 - "We aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). "
05/20/2008 - "Cetuximab improved overall survival in colorectal cancer patients in whom other treatments had failed."
12/01/2011 - "KRAS mutation status is being used as the sole biomarker to predict therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). "
|7.||capecitabine (Xeloda)FDA Link
04/01/2010 - "To date, the economic evaluation literature has consistently projected or found that capecitabine is not only a cost-effective treatment for adjuvant or for metastatic colorectal cancer (i.e., providing good value for money) but, furthermore, would actually be cost saving in the majority of country settings."
01/01/2007 - "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (mCRC). "
06/01/2004 - "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). "
07/01/2006 - "As the treatment for metastatic colorectal cancer, capecitabine showed at least comparable efficacy with a favorable safety profile to bolus 5-FU/LV. "
12/01/2003 - "Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer. "
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/15/2015 - "The clinical management of colorectal cancer patients has significantly improved because of the identification of novel therapeutic targets such as EGFR and VEGF. "
01/01/2011 - "Moreover, high P-LVD and high VEGF expression were significant negative prognostic parameters associated with a shorter disease-free interval in stage I colorectal cancer. "
11/01/2002 - "Early postoperative serum VEGF levels show significant fall and may help to identify the oncological status of colorectal cancer resections."
01/01/2015 - "Therefore, the simultaneous targeting of EGFR/VEGF and COX-2 may aid in blocking mCRC progression and improve the efficacy of existing therapies in colorectal cancer. "
02/01/2010 - "Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients."
|9.||Epidermal Growth Factor Receptor (EGF Receptor)IBA
09/01/2012 - "For metastatic colorectal cancer (mCRC) patients anti-EGFR (epidermal growth factor receptor) targeted therapy has markedly improved disease control and survival. "
03/01/2012 - "The identification of KRAS and BRAF mutations as predictive molecular alterations of resistance to EGF receptor monoclonal antibody therapy in metastatic colorectal cancer have significantly improved the selection of patients more likely to be eligible for the treatment with these targeted agents. "
03/01/2012 - "Epidermal growth factor receptor (EGFR) gene copy number evaluated by fluorescence in situ hybridisation (FISH) can discriminate among KRAS wild-type patients those with better outcome to EGFR-targeted therapy in metastatic colorectal cancer, further enhancing selection of patients. "
01/22/2015 - "The epidermal growth factor receptor (EGFR) antibody drugs are effective in a subset of colorectal cancers, but the molecular mechanisms of resistance are understood poorly. "
12/01/2009 - "Targeted therapy against the EGF receptor was shown to be effective in a subgroup of patients with KRAS wild-type colorectal cancer. "
|10.||panitumumab (Vectibix)FDA Link
09/01/2015 - "Panitumumab has proven efficacy in patients with metastatic or locally advanced colorectal cancer patients, provided that they have no activating KRAS mutation in their tumour. "
12/03/2007 - "In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). "
05/01/2007 - "Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer."
11/01/2015 - "Although the anti-EGFR monoclonal antibody panitumumab is effective in treating colorectal cancer, the occurrence of severe skin disorders often discontinues therapy. "
10/01/2012 - "Our findings suggested that panitumumab has great potential for effective treatment of patients with unresectable stageIV colorectal cancer."
|1.||Drug Therapy (Chemotherapy)
04/01/2004 - "In contrast, combination of anti-angiogenic therapy with chemotherapy was highly effective in an encouraging, large randomized phase III trial on metastatic colorectal cancer. "
02/01/2010 - "The survival of patients diagnosed with metastatic colorectal cancer in Alberta has improved in recent years; this is most likely attributable in large part to the use of chemotherapy."
11/01/2007 - "Neoadjuvant chemotherapy is a highly promising treatment modality for colorectal cancer. "
02/01/2006 - "Although the decision regarding colorectal cancer chemotherapy is now more complicated, our patients have certainly benefited from better response rates and most importantly, longer survival times."
02/01/2001 - "The "pharmacokinetic modulating chemotherapy" (PMC) regimen that we have advocated has proved to be highly effective in treating colorectal carcinoma. "
10/01/2010 - "Although progress in the treatment of patients with colorectal cancer (CRC) has resulted in improved median survival, most patients with metastatic CRC still die of their disease, and essentially all patients with early-stage disease must undergo surgical resection and subsequently face the possibility of adjuvant chemotherapy. "
05/01/2015 - "In the propensity score-matched cohort, patients with adjuvant chemotherapy had better overall survival than those without (P = 0.026).The present study demonstrated that adjuvant chemotherapy improved overall survival after curative resection for stage IV colorectal cancer. "
12/01/2008 - "This study aimed to retrospectively assess the efficacy of postoperative adjuvant chemotherapy in 77 patients who underwent curative resection for stage III colorectal cancer. "
11/01/2008 - "The present study was designed to retrospectively examine the efficacy of postoperative adjuvant chemotherapy in 107 patients with stage II primary colorectal cancer who underwent curative resection. "
03/01/2002 - "Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial."
|3.||Heterologous Transplantation (Xenotransplantation)
01/15/2015 - "RA also dramatically reduced angiogenesis in chick embryo chorioallantoic membrane (CAM), restrained the trunk angiogenesis in zebrafish, and suppressed angiogenesis and growth of human HCT-15 colorectal cancer xenograft in mice. "
07/01/2014 - "Enhanced therapeutic efficacy in vivo was observed in the MMP-2/9-targeting fusion protein dFv-LDP integrated combinations including: i) dFv-LDP and Ec-LDP-Hr, ii) dFv-LDP and enediyne-energized fusion protein Ec-LDP-Hr-AE, iii) dFv-LDP and Ec-LDP-Hr-AE plus DOX, and iv) dFv-LDP and GEM plus DOX against colorectal cancer HCT-15 xenograft in athymic mice. "
01/01/2013 - "To examine the in vivo therapeutic efficacy of PPP, mice implanted with human colorectal carcinoma xenografts underwent PPP treatment. "
12/10/2011 - "Further, in vivo biodistribution, therapeutic efficacy and biocompatibility of the SNP-CPT were evaluated in human colorectal cancer xenografts using in vivo fluorescence or bioluminescence optical imaging. "
09/01/1999 - "Appropriate experimental models based for example on xenografts of human colorectal cancer (HCRC) cells may help to find new therapeutic options. "
|4.||Combination Drug Therapy (Combination Chemotherapy)
10/01/2004 - "It was suggested that CPT-11+UFT-E combination chemotherapy was effective for advanced colorectal cancer."
01/01/2004 - "This case suggests that this combination chemotherapy of LV/5-FU, admitted in Japan, is effective against advanced colorectal cancer."
08/01/2000 - "These results suggest that this combination chemotherapy is feasible and effective in the treatment of advanced or recurrent colorectal cancer."
04/01/2013 - "Combination chemotherapy regimens have shown promising results in patients with metastatic colorectal cancer. "
11/15/1987 - "If validated with an in vivo test such as the nude mouse model, the MTT assay could be very useful in new drug screening for colorectal carcinoma, for examining combination chemotherapy for synergy, for exploring strategies for biochemical modulation, and perhaps in individualizing therapy when cell lines can be established from a patient."
01/01/2000 - "As such they should be very effective when used in chemoprevention studies and screening protocols for colorectal cancer."
08/01/2005 - "NEWER CONCEPTS AND THERAPIES IN UC 5-ADA-- 1. Remains drug of choice for induction and maintenance of remission in mild to moderate IC.1,2 2. Rare but increased incidence of renal disease exists but benefits outweigh risks.18-20 3. Chemoprevention of colorectal cancer in UC is promising and may be related to higher dose and a lessened degree of inflammation.29-36 4. Bioequivalence of all USA 5-ASA is established. "
09/01/2012 - "Some studies suggest that ursodeoxycholic may reduce the colorectal cancer risk, but to date the studies are small, mostly retrospective, and lacking in solid evidence to support use of UDCA for colorectal cancer chemoprophylaxis."
05/01/2012 - "The major goal of this study was to review combination chemoprevention for colorectal cancer by means of combining low doses of potential preventive agents to increase their chemoprophylaxis efficacy and to minimize toxicity."
01/01/2012 - "The purpose of this study is to assess the trends and dose-response effects of various medication possession ratios (MPR) of selective COX-2 inhibitor used for chemoprevention of colorectal cancer. "